Marshall Wace North America L.P. cut its position in SAGE Therapeutics Inc (NASDAQ:SAGE) by 7.3% in the third quarter, HoldingsChannel.com reports. The firm owned 489,148 shares of the biopharmaceutical company’s stock after selling 38,468 shares during the period. Marshall Wace North America L.P.’s holdings in SAGE Therapeutics were worth $69,092,000 as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Flinton Capital Management LLC boosted its position in shares of SAGE Therapeutics by 1,900.0% in the 2nd quarter. Flinton Capital Management LLC now owns 680 shares of the biopharmaceutical company’s stock valued at $106,000 after purchasing an additional 646 shares during the period. US Bancorp DE boosted its position in shares of SAGE Therapeutics by 5,593.3% in the 2nd quarter. US Bancorp DE now owns 854 shares of the biopharmaceutical company’s stock valued at $133,000 after purchasing an additional 839 shares during the period. Creative Planning acquired a new stake in shares of SAGE Therapeutics in the 2nd quarter valued at about $210,000. Tiverton Asset Management LLC acquired a new stake in shares of SAGE Therapeutics in the 2nd quarter valued at about $229,000. Finally, CIBC Asset Management Inc boosted its position in shares of SAGE Therapeutics by 26.4% in the 2nd quarter. CIBC Asset Management Inc now owns 1,633 shares of the biopharmaceutical company’s stock valued at $256,000 after purchasing an additional 341 shares during the period.
SAGE has been the subject of a number of research analyst reports. BidaskClub raised SAGE Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Thursday, August 30th. Canaccord Genuity set a $220.00 target price on SAGE Therapeutics and gave the company a “buy” rating in a research report on Thursday, November 1st. Leerink Swann initiated coverage on SAGE Therapeutics in a research report on Monday, November 12th. They issued an “underperform” rating and a $80.00 target price for the company. Oppenheimer set a $170.00 target price on SAGE Therapeutics and gave the company a “buy” rating in a research report on Tuesday, November 20th. Finally, Cowen reissued a “buy” rating and issued a $207.00 target price on shares of SAGE Therapeutics in a research report on Thursday, November 1st. Two investment analysts have rated the stock with a sell rating, thirteen have given a buy rating and one has issued a strong buy rating to the company’s stock. SAGE Therapeutics currently has an average rating of “Buy” and an average price target of $204.14.
SAGE Therapeutics stock traded down $2.59 during mid-day trading on Thursday, reaching $105.88. 402,203 shares of the company were exchanged, compared to its average volume of 487,952. SAGE Therapeutics Inc has a twelve month low of $100.75 and a twelve month high of $195.97. The stock has a market capitalization of $5.09 billion, a price-to-earnings ratio of -14.93 and a beta of 2.72.
SAGE Therapeutics (NASDAQ:SAGE) last issued its earnings results on Tuesday, November 6th. The biopharmaceutical company reported ($2.63) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.41) by ($0.22). During the same period last year, the firm earned ($1.97) earnings per share. As a group, equities analysts predict that SAGE Therapeutics Inc will post -7.58 EPS for the current year.
ILLEGAL ACTIVITY NOTICE: “SAGE Therapeutics Inc (SAGE) Shares Sold by Marshall Wace North America L.P.” was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece of content on another publication, it was illegally stolen and republished in violation of international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/12/06/sage-therapeutics-inc-sage-shares-sold-by-marshall-wace-north-america-l-p.html.
SAGE Therapeutics Profile
Sage Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system disorders. Its lead product candidate comprises brexanolone, a proprietary intravenous formulation of allopregnanolone that has completed III clinical trials for the treatment of post-partum depression (PPD).
Further Reading: What is a capital gain?
Want to see what other hedge funds are holding SAGE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SAGE Therapeutics Inc (NASDAQ:SAGE).
Receive News & Ratings for SAGE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAGE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.